Order Entry
United States
ContactUsLinkComponent
Alethia® C. difficile DNA amplification assay, Meridian Bioscience
Alethia® C. difficile DNA amplification assay, Meridian Bioscience
Catalog # 76437-450
Supplier:  Meridian
CAS Number:  
undefined
Alethia® C. difficile DNA amplification assay, Meridian Bioscience
Catalog # 76437-450
Supplier:  Meridian
Supplier Number:  480050
CAS Number:  
Restricted Products: To process your orders without delay, please provide the required business documentation to purchase this product.

To order chemicals, medical devices, or other restricted products please provide ID that includes your business name & shipping address via email [email protected] or fax 484.881.5997 referencing your VWR account number. Acceptable forms of ID are:

  • • State issued document with your organization's Federal Tax ID Number
  • • State issued document with your organization's Resale Tax ID Number
  • • City or County issued Business License
  • • State Department of Health Services License
  • • Any other ID issued by the State that includes the business name & address

* ATTN: California Customers may require additional documentation as part of the CA Health & Safety Code. Products that fall under this regulation will be placed on a mandatory 21-day hold after documentation is received. Avantor will not lift restrictions for residential shipping addresses.

Specifications

  • Description:
    Alethia® C. difficile
  • Environmentally Preferable:
  • Cat. No.:
    76437-450
  • Details:
    Molecular assay for the detection of C. difficile. Alethia® provides a quick, accurate and reliable molecular assay for C. difficile detection.

Specifications

About this item

The Alethia C. difficile DNA amplification assay, performed on the Alethia reader, is a qualitative in-vitro diagnostic test for the direct detection of toxigenic C. difficile in human stool specimens from pediatric and adult patients suspected of having Clostridium difficile-associated disease (CDAD).

  • Reduce the risk of missing a true positive with the accuracy of molecular

Fast, actionable results enable physicians to make informed decisions about the patient management and treatment resulting in reduced healthcare costs associated with isolation and antibiotics.